92 related articles for article (PubMed ID: 11370539)
21. [Follow-up of differentiated thyroid cancer patients using rhTSH--preliminary results].
Petrich T; Börner AR; Weckesser E; Soudah B; Otto D; Widjaja A; Hofmann M; Kreipe HH; Knapp WH
Nuklearmedizin; 2001 Feb; 40(1):7-14. PubMed ID: 11373937
[TBL] [Abstract][Full Text] [Related]
22. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
Robbins RJ; Tuttle RM; Sharaf RN; Larson SM; Robbins HK; Ghossein RA; Smith A; Drucker WD
J Clin Endocrinol Metab; 2001 Feb; 86(2):619-25. PubMed ID: 11158019
[TBL] [Abstract][Full Text] [Related]
23. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
[TBL] [Abstract][Full Text] [Related]
24. Comparison of FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan.
Wu HS; Huang WS; Liu YC; Yen RF; Shen YY; Kao CH
Anticancer Res; 2003; 23(5b):4235-8. PubMed ID: 14666632
[TBL] [Abstract][Full Text] [Related]
25. Non-131I-scintigraphy in the treatment and follow-up of thyroid cancer. Single-photon-emitters or FDG-PET?
Grünwald F; Briele B; Biersack HJ
Q J Nucl Med; 1999 Sep; 43(3):195-206. PubMed ID: 10568135
[TBL] [Abstract][Full Text] [Related]
26. [Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2)].
Dietlein M; Dressler J; Eschner W; Leisner B; Reiners C; Schicha H; ;
Nuklearmedizin; 2003 Jun; 42(3):123-5. PubMed ID: 12802477
[TBL] [Abstract][Full Text] [Related]
27. Technetium-99m-sestamibi uptake by recurrent Hurthle cell carcinoma of the thyroid.
Balon HR; Fink-BennetT D; Stoffer SS
J Nucl Med; 1992 Jul; 33(7):1393-5. PubMed ID: 1535374
[TBL] [Abstract][Full Text] [Related]
28. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
29. Conventional gamma and high energy probe for radioguided dissection of metastases in a patient with recurrent thyroid carcinoma with (99m)Tc-MIBI and (18)F-FDG.
Meller B; Sahlmann C; Horstmann O; Gerl J; Baehre M; Meller J
Nuklearmedizin; 2005; 44(3):N23-5. PubMed ID: 15997503
[No Abstract] [Full Text] [Related]
30. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
[TBL] [Abstract][Full Text] [Related]
31. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
[TBL] [Abstract][Full Text] [Related]
32. [99m-Tc-MIBI for recurrent and metastatic differentiated thyroid carcinoma].
Elser H; Henze M; Hermann C; Eckert W; Mende U
Nuklearmedizin; 1997 Jan; 36(1):7-12. PubMed ID: 9082340
[TBL] [Abstract][Full Text] [Related]
33. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.
Seabold JE; Gurll N; Schurrer ME; Aktay R; Kirchner PT
J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361
[TBL] [Abstract][Full Text] [Related]
34. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
35. Recombinant TSH-stimulated, radioguided differentiated thyroid carcinoma surgery.
Spieth ME; Standiford SB; Starkman ME; Gough J
Clin Med Res; 2003 Jan; 1(1):53-6. PubMed ID: 15931286
[TBL] [Abstract][Full Text] [Related]
36. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases.
Unal S; Menda Y; Adalet I; Boztepe H; Ozbey N; Alagöl F; Cantez S
J Nucl Med; 1998 Nov; 39(11):1897-902. PubMed ID: 9829579
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma.
Lee HJ; Rha SY; Jo YS; Kim SM; Ku BJ; Shong M; Kim YK; Ro HK
Am J Clin Oncol; 2007 Feb; 30(1):63-8. PubMed ID: 17278897
[TBL] [Abstract][Full Text] [Related]
38. Nuclear imaging in the management of thyroid carcinoma.
Cavalieri RR
Thyroid; 1996 Oct; 6(5):485-92. PubMed ID: 8936676
[TBL] [Abstract][Full Text] [Related]
39. Technetium-99m-furifosmin in the follow-up of differentiated thyroid carcinoma.
Brandt-Mainz K; Müller SP; Sonnenschein W; Bockisch A
J Nucl Med; 1998 Sep; 39(9):1536-41. PubMed ID: 9744338
[TBL] [Abstract][Full Text] [Related]
40. Comparison of different tracers in the follow up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Mikosch P; Kresnik E; Gomez I; Kumnig G; Matschnig S; Unterweger O; Dinges HP; Starlinger M
Acta Med Austriaca; 1999; 26(4):115-7. PubMed ID: 10526627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]